Loading clinical trials...
Loading clinical trials...
A Phase 3, Multicenter, Randomized, Double-Blind Study of the Efficacy and Safety of Rezafungin for Injection Versus the Standard Antimicrobial Regimen to Prevent Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (The ReSPECT Study)
Conditions
Interventions
Rezafungin for Injection
Posaconazole
+4 more
Locations
53
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
UCLA Center for Health Sciences
Los Angeles, California, United States
Stanford University School of Medicine
Stanford, California, United States
Augusta University Medical Center
Augusta, Georgia, United States
Rush University Medical Center
Chicago, Illinois, United States
University of Chicago
Chicago, Illinois, United States
Start Date
May 11, 2020
Primary Completion Date
January 29, 2026
Completion Date
January 29, 2026
Last Updated
April 13, 2026
NCT05421858
NCT01829204
NCT06510699
NCT04665037
NCT06105411
NCT06537726
Lead Sponsor
Mundipharma Research Limited
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions